Can-Fite Bolsters Obesity Franchise with Israeli Patent Grant
Event summary
- Can-Fite BioPharma secured an Israeli patent (No. 284463) covering the use of A3 adenosine receptor (A3AR) agonists, including Namodenoson, for fat loss and obesity treatment.
- This patent allowance complements existing IP protection in the US, Canada, and Australia, strengthening Can-Fite’s global intellectual property portfolio.
- A peer-reviewed study published in the International Journal of Obesity demonstrated the anti-obesity effect of Namodenoson.
- The global obesity therapeutics market is projected to reach $60.5 billion by 2030, with a CAGR of approximately 22%.
The big picture
Can-Fite is attempting to carve out a niche in the rapidly expanding obesity therapeutics market, currently dominated by GLP-1 agonists. The newly granted patent strengthens their IP position, but the company faces the challenge of demonstrating Namodenoson’s differentiated benefits and navigating a competitive landscape with established players. The $60.5 billion market size by 2030 represents a significant opportunity, but requires substantial investment and execution.
What we're watching
- Clinical Trials
- The success of Namodenoson’s ongoing Phase III trial for advanced liver cancer and Phase IIb trial for MASH will be critical in establishing its overall clinical value and justifying further investment in its obesity franchise.
- Competitive Landscape
- The market is dominated by GLP-1 receptor agonists; Can-Fite must demonstrate a clear advantage—either in efficacy, safety, or cost—to gain significant market share.
- Partnering Strategy
- Given the capital intensity of drug development, Can-Fite’s ability to secure strategic partnerships to co-develop and commercialize Namodenoson will be a key determinant of its long-term success.
Related topics